Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B

NCT01425723 is registered in ClinicalTrials.gov with Bioverativ Therapeutics Inc. as lead sponsor.

NCT NCT01425723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01425723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B
Lead sponsor
Bioverativ Therapeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 8, 2011
Completion date
October 31, 2017
Enrollment
120 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

severe hemophilia b